References

  1. Fasola FA, Eteng KI, Shokunbi WA, Akinyemi JO, Salako BL. Renal status of multiple myeloma patients in Ibadan, Nigeria. Ann Ib Postgrad Med. 2012; 10(2):28-33. PubMed | Google Scholar

  2. Lifetime risk was calculated by the Statistical Information Team at Cancer Research UK, 201 www.cancerresearchuk.org. PubMed | Google Scholar

  3. Esteve J, Benhamou E, Raymond L. Descriptive epidemiology [IARC Scientific Publications No.128] (link is external), p 67-68. Lyon: International Agency for Research on Cancer; 1994. PubMed | Google Scholar

  4. Waller J, Robb K, Stubbings S, Ramirez A, Macleod U, Austoker J et al. Awareness of cancer symptoms and anticipated help seeking among ethnic minority groups in England (link is external). Brit J Cancer. 2009; 101Suppl 2:S24-30. PubMed | Google Scholar

  5. Robb K, Stubbings S, Ramirez A, Macleod U, Austoker J, Waller J et al. Public awareness of cancer in Britain: a population-based survey of adults. Brit J Cancer. 2009;101Suppl 2:S18-23. PubMed | Google Scholar

  6. Anetor JI, Ajose FI, Akingbola TS. A Case Of IgA Multiple Myeloma: nutritional perspective in diagnostic testing. Indian J Clin Biochem. 2005; 20 (1) 193-197. PubMed | Google Scholar

  7. Altekruse SF, Kosary CL, Krapcho M. SEER Cancer Statistics Review, 1975?200 Bethesda: National Cancer Institute; 2010. Google Scholar

  8. Waxman AJ, Mink PJ, Devesa SS, Anderson WF, Weiss BM, Kristinsson SY et al. Racial disparities in incidence and outcome in multiple myeloma: a population basedstudy. Blood. 2010; 116: 5501-5506. PubMed | Google Scholar

  9. Greenberg AJ, Philip S, Paner A, Velinova S, Badros A, Catchatourian R et al. Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-centre study. Blood Cancer J. 2015; 5:e271. Google Scholar

  10. Fonseca R. Many and multiple myeloma(s). Leukemia. 2003;17:1943-1944. Google Scholar

  11. Madu AJ, Ocheni S, Nwagha TA, Ibegbulam OG, Anike US. Multiple myeloma in Nigeria: An insight to the clinical, laboratory features, and outcomes. Niger J Clin Pract. 2014 Mar-Apr;17(2):212-7. Google Scholar

  12. Saad F, Lipton A, Cook R, Chen Y, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007 Oct 15;110(8):1860-7. PubMed | Google Scholar

  13. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002; 359:1761-1767. PubMed | Google Scholar

  14. Oyajobi BO. Multiple myeloma/hypercalcemia. Arthritis Research & Therapy. 2007; 9(Suppl 1): S4. PubMed | Google Scholar

  15. Oyajobi BO, Mundy GR. Pathophysiology of myeloma bone disease. In: Gahrton G, Durie BGM, Samson DS, editor. Multiple Myeloma and Related Disorders. 2. London, UK: Arnold; 2004. pp. 74-88. Google Scholar

  16. Tuttle KR, Kunau RT, Loveridge N, Mundy GR. Altered renal calcium handling in hypercalcemia of malignancy. J Am Soc Nephrol. 1991 Aug;2(2):191-9. PubMed | Google Scholar

  17. Sinohara H, Matsuura K. Does catalytic activity of Bence Jones protein contribute to the pathogenesis of multiple myeloma. Appl Biochem Biotechnol. 2000;83(1-3):85-92;discussion 93-4;145-53. PubMed | Google Scholar

  18. Heher EC, Rennke HG, Laubach JP, Richardson PG. Kidney disease and Multiple myeloma. Clin J Am Soc Nephrol. 2013;8(11):2007-17. PubMed | Google Scholar